UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis

Journal of Atherosclerosis and Thrombosis, 2013, Vol.20(2), pp.123-133

2013

Volltextzugriff (PDF)

The role of lipids in renal disease: Future challenges

Kidney international, 2000-04, Vol.57 (S75), p.S27-S31

Keane, William F.

2000

Volltextzugriff (PDF)

Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study

Clinical journal of the American Society of Nephrology, 2006-07, Vol.1 (4), p.761-767

2006

Volltextzugriff (PDF)

Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables

Journal of clinical lipidology, 2017-01, Vol.11 (1), p.102-109

2017

Volltextzugriff (PDF)

The missing link: The parental voice in Bring Your Own Device (BYOD) programs

Education and information technologies, 2022-07, Vol.27 (6), p.7699-7719

2022

Volltextzugriff (PDF)

Early detection of kidney disease in community settings: the kidney early evaluation program (KEEP)

American journal of kidney diseases, 2003-07, Vol.42 (1), p.22-35

2003

Volltextzugriff (PDF)

Beyond traditional literacy: Learning and transformative practices using ICT

Education and information technologies, 2016-07, Vol.21 (4), p.769-781

2016

Volltextzugriff (PDF)

Parents’ expectations, perceptions and concerns when schools implement a 1:1 program

Education and information technologies, 2018-07, Vol.23 (4), p.1447-1464

2018

Volltextzugriff (PDF)

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

Circulation (New York, N.Y.), 2004-08, Vol.110 (8), p.921-927

2004

Volltextzugriff (PDF)

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

The New England journal of medicine, 2001-09, Vol.345 (12), p.861-869

2001

Volltextzugriff (PDF)

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL

Kidney international, 2004-06, Vol.65 (6), p.2309-2320

2004

Volltextzugriff (PDF)

Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy : Post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial

Journal of the American Society of Nephrology, 2007-05, Vol.18 (5), p.1540-1546

2007

Volltextzugriff (PDF)

Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure

Kidney international, 2001-12, Vol.60 (6), p.2205-2214

2001

Volltextzugriff (PDF)

Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation

American journal of kidney diseases, 1999-05, Vol.33 (5), p.1004-1010

1999

Volltextzugriff (PDF)

Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure

Kidney international, 2001-01, Vol.59 (1), p.246-251

2001

Volltextzugriff (PDF)

Metabolic pathogenesis of cardiorenal disease

American journal of kidney diseases, 2001-12, Vol.38 (6), p.1372-1375

Keane, William F.

2001

Volltextzugriff (PDF)

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study

Kidney international, 2003-04, Vol.63 (4), p.1499-1507

2003

Volltextzugriff (PDF)

Identification of persons at high risk for kidney disease via targeted screening: The NKF Kidney Early Evaluation Program

Kidney international, 2003-02, Vol.63 (S83), p.S50-S55

2003

Volltextzugriff (PDF)

Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy

Kidney international, 2004-09, Vol.66 (3), p.1131-1138

2004

Volltextzugriff (PDF)

Diabetic Nephropathy

Diabetes care, 2003-01, Vol.26 (suppl 1), p.s94-s98

2003

Volltextzugriff (PDF)

Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study

Diabetes care, 2008-03, Vol.31 (3), p.445-447

2008

Volltextzugriff (PDF)

Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program

Kidney international, 2005-04, Vol.67 (4), p.1483-1488

2005

Volltextzugriff (PDF)

The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

Journal of the renin-angiotensin-aldosterone system, 2000-12, Vol.1 (4), p.328-335

2000

Volltextzugriff (PDF)

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study

Clinical and experimental nephrology, 2006-09, Vol.10 (3), p.193-200

2006

Volltextzugriff (PDF)

Adult peritoneal dialysis-related peritonitis treatment recommendations : 2000 UPDATE

Peritoneal dialysis international, 2000-07, Vol.20 (4), p.396-411

2000

Volltextzugriff (PDF)

1 – 25 von 325

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(300)
Mit Volltextzugriff
(242)

Publikationsform

Sprache

Englisch
(325)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis

The role of lipids in renal disease: Future challenges

Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study

Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables

The missing link: The parental voice in Bring Your Own Device (BYOD) programs

Early detection of kidney disease in community settings: the kidney early evaluation program (KEEP)

Beyond traditional literacy: Learning and transformative practices using ICT

Parents’ expectations, perceptions and concerns when schools implement a 1:1 program

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL

Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy : Post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial

Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure

Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation

Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure

Metabolic pathogenesis of cardiorenal disease

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study

Identification of persons at high risk for kidney disease via targeted screening: The NKF Kidney Early Evaluation Program

Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy

Diabetic Nephropathy

Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study

Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program

The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study

Adult peritoneal dialysis-related peritonitis treatment recommendations : 2000 UPDATE

Suchergebnisse filtern